Major Depressive Disorder Market Trends Support A 3.9% CAGR Outlook Through The Forecast Period

The major depressive disorder market is poised for steady advancement in the coming years, driven by various evolving factors in mental health care. Understanding the market's current valuation, innovation trends, leading players, and segment breakdown offers valuable insight into its future trajectory.

Projected Market Valuation and Growth Outlook for the Major Depressive Disorder Market
The major depressive disorder market is forecasted to expand to $7.49 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.9%. This upward trend is influenced by an increasing mental health burden tied to lifestyle stressors, a surge in the use of digital platforms for mental health, heightened demand for tailored depression therapies, broader insurance coverage for mental health services, and ongoing advancements in neuromodulation therapies. Additionally, key trends expected to shape the market include greater adoption of combination therapies, rising interest in non-invasive brain stimulation methods, improved awareness and diagnosis rates for depression, expansion of telepsychiatry and remote mental health services, and growing acceptance of innovative, rapid-acting antidepressants.

The major depressive disorder market size has grown steadily in recent years. It will grow from $6.26 billion in 2025 to $6.44 billion in 2026 at a compound annual growth rate (CAGR) of 2.9%. The growth in the historic period can be attributed to increasing prevalence of depressive disorders, growing societal awareness of mental health, wider availability of antidepressant medications, expansion of psychiatric care infrastructure, improved diagnostic guidelines for mood disorders.

Download a free sample of the major depressive disorder market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Primary Companies Leading the Major Depressive Disorder Market
The major depressive disorder sector is dominated by several prominent firms such as Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., and Vistagen Therapeutics Inc.

In a notable development, AbbVie Inc., a US healthcare and biopharmaceutical company, acquired bretisilocin from Gilgamesh Pharmaceuticals, Inc. in October 2025 for an undisclosed sum. This acquisition is part of AbbVie's strategy to bolster its psychiatry and neuroscience portfolio by incorporating a next-generation, short-acting psychedelic-derived candidate aimed at accelerating treatment options for major depressive disorder. Gilgamesh Pharmaceuticals is a clinical-stage biotechnology firm specializing in innovative psychedelic-derived and psychoplastogen therapies, including bretisilocin, which is a Phase 2 investigational 5-HT2A receptor agonist targeting moderate-to-severe major depressive disorder.

View the full major depressive disorder market report:
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Shaping the Future of Major Depressive Disorder Treatments
Leading organizations are increasingly focused on developing prescription digital therapeutics (PDTs), which are software-based medical interventions designed to improve access to evidence-based psychotherapy, support partial responders, and facilitate remote, measurement-driven care. Unlike traditional antidepressants or in-person therapy, PDTs deliver standardized, repeatable, remotely supervised behavioral treatments that complement medication or address gaps in provider availability.

A prominent example occurred in April 2024 when Otsuka Pharmaceutical Co., headquartered in Japan, partnered with Click Therapeutics to launch Rejoyn (known as CT-152), a prescription digital therapeutic authorized by the U.S. FDA as an adjunct treatment for adults with major depressive disorder on antidepressant medication. Rejoyn is a six-week smartphone program centered on clinically validated cognitive-emotional brain-training exercises and brief therapeutic lessons designed to improve emotional regulation. Patients complete scheduled sessions on their smartphones under clinician supervision, benefiting from remote adherence reminders and a neuromodulatory design targeting neural networks involved in emotion processing. Its FDA clearance as a medical device distinguishes it from conventional wellness apps and reinforces its clinical credibility.

Detailed Segmentation of the Major Depressive Disorder Market
The major depressive disorder market is organized into several key segments:

1) By Treatment Type: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and Other Treatments.
2) By Diagnostic Approach: Psychiatric Evaluations and Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria.
3) By End-User Category: Clinics, Hospitals, and Other End-Users.

Further subcategories include:

- Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy.
- Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants.
- Electroconvulsive Therapy: Unilateral ECT, Bilateral ECT, Modified ECT.
- Transcranial Magnetic Stimulation: Repetitive TMS (rTMS), Deep TMS (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS).
- Other Treatments: Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, and additional psychotherapeutic approaches.

This segmentation provides a comprehensive framework for understanding the diverse treatment modalities and diagnostic practices that compose the major depressive disorder market landscape.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.